Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.8 EUR | -3.12% | -3.12% | 0.00% |
Apr. 04 | 1000mercis: RNPG increased by half in 2023 | CF |
Apr. 01 | Healthcare firm PACS Group eyes up to $3.25 bln valuation in US IPO | RE |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 123.2 | 70.88 | 59.23 | 48.41 | 47.53 | 59.22 |
Enterprise Value (EV) 1 | 111.5 | 71.49 | 63.19 | 45.4 | 43.35 | 57.32 |
P/E ratio | 24.5 x | 16.5 x | 24.7 x | -7.12 x | 45.8 x | 26.7 x |
Yield | 4.64% | 1.22% | - | - | - | 37.2% |
Capitalization / Revenue | 2 x | 1.01 x | 0.82 x | 0.81 x | 0.68 x | 0.75 x |
EV / Revenue | 1.81 x | 1.01 x | 0.88 x | 0.76 x | 0.62 x | 0.73 x |
EV / EBITDA | 10.1 x | 8.28 x | 9.27 x | -25.8 x | 9.17 x | 12.9 x |
EV / FCF | 1,226 x | -29.5 x | -25.4 x | 4.45 x | 5.51 x | -22.4 x |
FCF Yield | 0.08% | -3.38% | -3.94% | 22.5% | 18.1% | -4.46% |
Price to Book | 2.23 x | 1.37 x | 1.22 x | 1.22 x | 1.44 x | 1.69 x |
Nbr of stocks (in thousands) | 2,856 | 2,881 | 2,632 | 2,554 | 2,160 | 2,161 |
Reference price 2 | 43.14 | 24.60 | 22.50 | 18.95 | 22.00 | 27.40 |
Announcement Date | 4/30/18 | 4/30/19 | 4/30/20 | 4/30/21 | 4/14/22 | 4/13/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 61.69 | 70.52 | 72.21 | 60.04 | 70.21 | 78.92 |
EBITDA 1 | 11 | 8.635 | 6.817 | -1.761 | 4.729 | 4.439 |
EBIT 1 | 7.467 | 5.317 | 2.207 | -6.31 | 0.481 | 1.798 |
Operating Margin | 12.1% | 7.54% | 3.06% | -10.51% | 0.69% | 2.28% |
Earnings before Tax (EBT) 1 | 7.18 | 5.432 | 2.504 | -7.08 | 0.879 | 1.922 |
Net income 1 | 5.28 | 4.239 | 2.502 | -6.796 | 1.044 | 2.22 |
Net margin | 8.56% | 6.01% | 3.47% | -11.32% | 1.49% | 2.81% |
EPS 2 | 1.760 | 1.490 | 0.9100 | -2.661 | 0.4800 | 1.027 |
Free Cash Flow 1 | 0.091 | -2.419 | -2.493 | 10.21 | 7.86 | -2.554 |
FCF margin | 0.15% | -3.43% | -3.45% | 17.01% | 11.19% | -3.24% |
FCF Conversion (EBITDA) | 0.83% | - | - | - | 166.21% | - |
FCF Conversion (Net income) | 1.72% | - | - | - | 752.86% | - |
Dividend per Share 2 | 2.000 | 0.3000 | - | - | - | 10.20 |
Announcement Date | 4/30/18 | 4/30/19 | 4/30/20 | 4/30/21 | 4/14/22 | 4/13/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 0.6 | 3.97 | - | - | - |
Net Cash position 1 | 11.7 | - | - | 3 | 4.18 | 1.9 |
Leverage (Debt/EBITDA) | - | 0.0699 x | 0.5819 x | - | - | - |
Free Cash Flow 1 | 0.09 | -2.42 | -2.49 | 10.2 | 7.86 | -2.55 |
ROE (net income / shareholders' equity) | 9.44% | 8.2% | 5.2% | -15.5% | 2.87% | 6.52% |
ROA (Net income/ Total Assets) | 4.65% | 3.4% | 1.47% | -4.21% | 0.34% | 1.36% |
Assets 1 | 113.6 | 124.7 | 170.1 | 161.5 | 311.1 | 162.9 |
Book Value Per Share 2 | 19.30 | 18.00 | 18.40 | 15.50 | 15.30 | 16.20 |
Cash Flow per Share 2 | 8.190 | 6.970 | 5.250 | 7.780 | 8.970 | 7.190 |
Capex 1 | 1.32 | 3.48 | 3.55 | 2.25 | 1 | 1.05 |
Capex / Sales | 2.14% | 4.93% | 4.92% | 3.74% | 1.42% | 1.33% |
Announcement Date | 4/30/18 | 4/30/19 | 4/30/20 | 4/30/21 | 4/14/22 | 4/13/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 57.23M | |
+24.29% | 27.88B | |
+10.84% | 18.78B | |
+8.39% | 13.65B | |
-3.58% | 11.88B | |
+7.89% | 10.86B | |
+7.47% | 4.45B | |
-12.44% | 3.74B | |
+35.03% | 3.4B | |
+16.26% | 3.31B |
- Stock Market
- Equities
- ALMIL Stock
- Financials 1000mercis